Current status of gynecologic cancer in Japan
Open Access
- 1 January 2009
- journal article
- Published by Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy in Journal of Gynecologic Oncology
- Vol. 20 (2) , 67-71
Abstract
Ushijima K. J Gynecol Oncol. 2009 Jun;20(2):67-71. http://dx.doi.org/10.3802/jgo.2009.20.2.67Keywords
This publication has 9 references indexed in Scilit:
- Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic OncologyJournal of Clinical Oncology, 2008
- Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group studyGynecologic Oncology, 2008
- Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young WomenJournal of Clinical Oncology, 2007
- Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.Oncology Reports, 2006
- A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinomaGynecologic Oncology, 2005
- Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcomeCancer Letters, 2001
- Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.2000
- Clinical characteristics of clear cell carcinoma of the ovaryCancer, 2000
- Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancerCancer Letters, 1998